Abstract
Since the outbreak of the COVID-19 in 2021, the pharmaceutical industry has received a significant impact. Abbvie, one of the top research-based biopharmaceutical companies around the world, has faced a large amount of challenges during this period. To explore Abbvie's operating status during this particular time, we have studied its annual report for 2021 and provided an analysis and assessment. This paper summarizes Abbvie's complex accounting policies regarding revenue recognition, research and development expenses, pensions and other post-employment benefits, and analyzes the company's trends in revenue and net income over the last 5 years in order to make basic projections for the next developments. In addition, the paper also calculates various financial ratios to obtain the financial performance of the company for the current year, and derives its short-term solvency, long-term solvency, asset management and profitability. Finally, the paper summarizes the risks that Abbvie is facing and the strategies to deal with them, in order to better expose the problems faced by the company and help it to better define its development direction.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
